Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr ; 137(10): 2185-9, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17884995

ABSTRACT

The cardioprotective effect of consuming cruciferous vegetables may be attributed to a number of unique indole-based compounds. We investigated the potential role and mechanism of action of an indole-based compound, indole-3-carbinol (I-3-C), on apolipoprotein B-100 (apoB) production using HepG2 cells. I-3-C reduced apoB secretion into the media dose dependently by 56% at 100 micromol/L. Relative to the untreated control cells, no change in the density of the secreted lipoproteins was noted. Significant decreases in cellular lipid synthesis, including triglycerides (TG) and cholesterol esters (CE), were observed in cells treated with I-3-C, indicating that limited lipid availability is a major factor in the regulation of apoB secretion. The decrease in TG synthesis was associated with significantly decreased diacylglycerol acyltransferase-1 and -2 activity and reduced fatty acid synthase (FASN) gene expression. The decreased CE synthesis was associated with significantly decreased acyl CoA:cholesterol acyltransferase gene expression and activity. The effect on FASN was shown to be mediated by sterol regulatory element binding protein-1, an important transcription factor involved in fatty acid synthesis. Further investigative work revealed that LDL uptake and fatty acid oxidation were not involved in the I-3-C-mediated reduction of apoB secretion. The results indicate that plant indoles have beneficial effects on lipid synthesis that could contribute to their potential cardioprotective effect.


Subject(s)
Apolipoproteins B/metabolism , Brassicaceae/metabolism , Indoles/pharmacology , Albumins/metabolism , Anticarcinogenic Agents/pharmacology , Apolipoproteins B/genetics , Cell Line , Cholesterol, LDL/metabolism , Dose-Response Relationship, Drug , Fatty Acids/metabolism , Gene Expression Regulation/drug effects , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Indoles/metabolism , Lipid Peroxidation , Lipogenesis/drug effects , Molecular Structure , Sterol Regulatory Element Binding Proteins/genetics , Sterol Regulatory Element Binding Proteins/metabolism
2.
Life Sci ; 79(4): 365-73, 2006 Jun 20.
Article in English | MEDLINE | ID: mdl-16497336

ABSTRACT

The present study was undertaken to determine whether supplementation with polymethoxylated flavones (PMFs) could ameliorate the fructose-induced hypertriglyceridemia and other metabolic abnormalities associated with insulin resistance (IR) in hamsters. Following feeding with the fructose diet, hamsters were supplemented orally with PMF-L or PMF-H (62.5 and 125 mg/kg/day) for 4 weeks. Both PMF-treated groups showed a statistically significant (p<0.05) decrease in serum triglyceride (TG) and cholesterol levels compared to the fructose-fed control group. The fructose control group at the end of the study showed elevated serum insulin and impaired insulin sensitivity (glucose intolerance). On the other hand, PMF-supplemented groups showed a reversal in these metabolic defects, including a decrease in insulin level and an improvement in glucose tolerance. PMF supplementation also reduced TG contents in the liver and heart and was able to regulate adipocytokines by significantly suppressing TNF-alpha, INF-gamma, IL-1beta and IL-6 expression and increasing adiponectin in IR hamsters. The mechanism of PMF on the activation of peroxisome proliferator-activated receptors (PPAR) was also explored. PMF-H supplementation significantly increased PPARalpha and PPARgamma protein expression in the liver. This is the first report of positive effects of PMF on adipocytokine production and on PPAR expression in IR hamsters. This study suggests that PMF can ameliorate hypertriglyceridemia and its anti-diabetic effects may occur as a consequence of adipocytokine regulation and PPARalpha and PPARgamma activation.


Subject(s)
Citrus/chemistry , Flavones/therapeutic use , Hypercholesterolemia/drug therapy , Hypolipidemic Agents/therapeutic use , Insulin Resistance , Adipocytes/drug effects , Adipocytes/metabolism , Administration, Oral , Animals , Blood Glucose/drug effects , Cholesterol/blood , Cricetinae , Cytokines/metabolism , Disease Models, Animal , Fructose/administration & dosage , Fructose/pharmacology , Glucose Tolerance Test , Homeostasis/drug effects , Hypercholesterolemia/etiology , Lipids/blood , Liver/drug effects , Liver/metabolism , Male , Mesocricetus , PPAR gamma/drug effects , PPAR gamma/metabolism , Plant Extracts/therapeutic use , Triglycerides/blood
3.
Metabolism ; 54(3): 403-9, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15736121

ABSTRACT

Over-accumulation of triglyceride (TG) in insulin-sensitive tissues is associated with the development of insulin resistance. We investigated whether enhanced de novo lipogenesis via diacylglycerol acyltransferase (DGAT) may contribute to the over-accumulation of TG in various tissues (liver, adipose, muscle, and intestine) using 2 well-characterized hyperlipidemic, insulin-resistant hamster models. In general, a marked increase in TG accumulation was noted in most tissues. Interestingly, the increase in TG accumulation corresponded to an increase in microsomal DGAT activity which ranged from 114% to 575% in all of the examined tissues (n = 7 per group). To delineate the mechanism for the increase in DGAT activity, we measured the expression of DGAT-1 and DGAT-2 messenger RNA by relative reverse transcriptase polymerase chain reaction (RT-PCR). In general, DGAT gene expression changed with DGAT-1 changing the most in the liver and adipose tissue, whereas DGAT-2 showed responses mainly in muscle and intestine. The increases in messenger RNA expression were not remarkable (averaging 35%; n = 4 per group) indicating that posttranscriptional mechanism(s) may play a larger role in regulating DGAT activity. In summary, the data suggest that elevated DGAT activity/expression and the subsequent increase in de novo lipogenesis could in part induce the insulin-resistant state.


Subject(s)
Acyltransferases/metabolism , Diet , Hyperlipidemias/enzymology , Insulin Resistance , Triglycerides/metabolism , Acyltransferases/genetics , Adipose Tissue/enzymology , Adipose Tissue/metabolism , Animals , Cholesterol/blood , Cricetinae , Diacylglycerol O-Acyltransferase , Dietary Fats/administration & dosage , Fatty Acids, Nonesterified/blood , Fructose/administration & dosage , Gene Expression , Hyperlipidemias/metabolism , Insulin/blood , Intestinal Mucosa/metabolism , Intestines/enzymology , Liver/enzymology , Liver/metabolism , Male , Mesocricetus , Muscles/enzymology , Muscles/metabolism , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction , Triglycerides/blood
4.
Atherosclerosis ; 176(2): 247-53, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15380446

ABSTRACT

The purpose of the present study was to examine the role of taxifolin, a plant flavonoid, on several aspects involving apolipoprotein B (apoB) secretion and triglyceride (TG) availability in HepG2 cells. Taxifolin was shown by ELISA to markedly reduce apoB secretion under basal and lipid-rich conditions up to 63% at 200 micromol/L. As to the mechanism underlying this effect, we examined whether taxifolin exerted its effect by limiting TG availability in the microsomal lumen essential for lipoprotein assembly. Taxifolin was shown to inhibit microsomal TG synthesis by 37% and its subsequent transfer into the lumen (-26%). The reduction in synthesis was due to a decrease in diacylglycerol acyltransferase (DGAT) activity (-35%). The effect on DGAT activity was found to be non-competitive and non-transcriptional in nature. Both DGAT-1 and DGAT-2 mRNA expression remained essentially unchanged suggesting the point of regulation may be at the post-transcriptional level. Evidence is accumulating that microsomal triglyceride transfer protein (MTP) is also involved in determining the amount of lumenal TG available for lipoprotein assembly and secretion. Taxifolin was shown to inhibit this enzyme by 41%. Whether the reduction in TG accumulation in the microsomal lumen is predominantly due to DGAT and/or MTP activity remains to be addressed. In summary, taxifolin reduced apoB secretion by limiting TG availability via DGAT and MTP activity.


Subject(s)
Acyltransferases/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carrier Proteins/pharmacology , Flavonols/pharmacology , Quercetin/analogs & derivatives , Quercetin/pharmacology , Apolipoproteins B/metabolism , Carcinoma, Hepatocellular/pathology , Diacylglycerol O-Acyltransferase , Enzyme-Linked Immunosorbent Assay , Humans , Liver Neoplasms/pathology , Tumor Cells, Cultured/pathology
5.
J Nutr ; 134(6): 1340-6, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15173394

ABSTRACT

The present study examined the role of xanthohumol (XN), a plant chalcone, on apolipoprotein B (apoB) and triglyceride (TG) synthesis and secretion, using HepG2 cells as the model system. The data indicated that XN decreased apoB secretion in a dose-dependent manner under both basal and lipid-rich conditions (as much as 43% at 15 micromol/L). This decrease was associated with increased cellular apoB degradation. To determine the mechanism underlying this effect, we examined triglyceride availability, a major factor in the regulation of apoB secretion. XN inhibited the synthesis of TG in the microsomal membrane and the transfer of this newly synthesized TG to the microsomal lumen (decreases of 26 and 64%, respectively, under lipid-rich conditions), indicating that TG availability is a determining factor in the regulation of apoB secretion under the experimental conditions. The inhibition of TG synthesis was caused by a reduction in diacylglycerol acyltransferase (DGAT) activity, which corresponded to a decrease in DGAT-1 mRNA expression, but not DGAT-2 expression. Microsomal triglyceride transfer protein (MTP) may also control the rate of TG transfer from the microsomal membrane to the active lumenal pool. XN decreased MTP activity in a dose-dependent manner (as much as 30%). Whether the reduction in TG accumulation in the microsomal lumen is predominantly due to DGAT and/or MTP activity remains unknown. In summary, the data suggest that xanthohumol is a potent inhibitor of apoB secretion.


Subject(s)
Apolipoproteins B/antagonists & inhibitors , Propiophenones/pharmacology , Triglycerides/antagonists & inhibitors , Acyltransferases/antagonists & inhibitors , Acyltransferases/genetics , Carrier Proteins/antagonists & inhibitors , Cell Line, Tumor , Diacylglycerol O-Acyltransferase , Dose-Response Relationship, Drug , Endoplasmic Reticulum/metabolism , Flavonoids , Golgi Apparatus/metabolism , Humans , Propiophenones/administration & dosage , RNA, Messenger/antagonists & inhibitors
6.
Lipids ; 39(2): 143-51, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15134141

ABSTRACT

The purpose of the present study was to examine the role of tangeretin, a polymethoxylated flavone from citrus fruits, on the regulation of apolipoprotein B (apoB) and lipid metabolism in the human hepatoma cell-line HepG2. The marked reduction in apoB secretion observed in cells incubated with 72.8 microM tangeretin was rapid, apoB-specific, and partly reversible. The reduction also was observed under lipid-rich conditions and found to be insensitive to proteasomal degradation of nascent apoB. We followed our study by examining lipid synthesis and mass. A 24-h exposure of cells to 72.8 microM tangeretin decreased intracellular synthesis of cholesteryl esters, free cholesterol, and TAG by 82, 45, and 64%, respectively; tangeretin also reduced the mass of cellular TAG by 37%. The tangeretin-induced suppression of TAG synthesis and mass were associated with decreased activities of DAG acyltransferase (up to -39.0 +/- 3.0% vs. control) and microsomal triglyceride transfer protein (up to -35.5 +/- 2.5% vs. control). Tangeretin was also found to activate the peroxisome proliferator-activated receptor, a transcription factor with a positive regulatory impact on FA oxidation and TAG availability (up to 36% increase vs. control). The data suggest that tangeretin modulates apoB-containing lipoprotein metabolism through multiple mechanisms.


Subject(s)
Apolipoproteins B/drug effects , Apolipoproteins B/metabolism , Carcinoma, Hepatocellular/pathology , Flavones/pharmacology , Acyltransferases/drug effects , Acyltransferases/metabolism , Carcinoma, Hepatocellular/metabolism , Carrier Proteins/drug effects , Carrier Proteins/metabolism , Cell Line, Tumor , Diacylglycerol O-Acyltransferase , Down-Regulation/drug effects , Humans , Peroxisome Proliferator-Activated Receptors/drug effects , Peroxisome Proliferator-Activated Receptors/metabolism , Triglycerides/biosynthesis , Triglycerides/chemistry
7.
Lipids ; 37(7): 647-52, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12216835

ABSTRACT

Recent studies have yielded evidence that plant flavonoids reduce hepatic lipid and apolipoprotein B (apoB) secretion. However, the possible role of flavonoids in regulating lipid and apoB secretion by the intestine has not been studied. The purpose of our study was to examine the effects of quercetin, a common dietary flavonoid, on TAG and apoB secretion in a human intestinal cell-line, CaCo-2. Differentiated postconfluent CaCo-2 cells grown on filters and pretreated with quercetin for 8 h were shown by ELISA to inhibit basolateral apoB secretion in a dose-dependent manner. At 15 microM, the secretion of both apoB-100 and apoB-48 were inhibited similarly. This effect was shown to be specific, as quercetin did not affect the incorporation of [35S]methionine/cysteine into secreted TCA-precipitable proteins. To determine the mechanism underlying this inhibitory effect, we examined two regulatory points: TAG availability and lipid transfer to the lipoprotein particle. Quercetin inhibited TAG synthesis under both basal and lipid-rich conditions, indicating that lipid availability is a determining factor in the regulation of apoB secretion by quercetin. The reduction was due at least in part to a decrease in diacylglycerol acyltransferase activity. We next examined lipid transfer or lipidation of the lipoprotein particle by analyzing microsomal TAG transfer protein (MTP) activity. Quercetin decreased MTP activity moderately. In summary, the data demonstrated that pharmacological concentrations of quercetin are a potent inhibitor of intestinal apoB secretion and that reduced lipid availability and lipidation in the lipoprotein assembly step are the mechanism for the suppression of apoB-containing lipoprotein secretion by quercetin in CaCo-2 cells.


Subject(s)
Acyltransferases/metabolism , Apolipoproteins B/metabolism , Carrier Proteins/metabolism , Intestines/drug effects , Quercetin/pharmacology , Apolipoprotein B-100 , Apolipoprotein B-48 , Blotting, Western , Caco-2 Cells , Diacylglycerol O-Acyltransferase , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Humans , Intestinal Mucosa/metabolism , Molecular Structure , Quercetin/chemistry , Triglycerides/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...